US equities
|
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
MU
$877.55
▲+2.46%
NVDA
$210.96
▼-0.59%
SPCX
$147.49
▲+1.89%
AAPL
$347.73
▼-0.14%
TSLA
$372.22
▼-0.63%
SNDK
$1,238.03
▼-1.82%
META
$642.62
▼-0.96%
AMD
$516.79
▲+1.74%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Articles published by NKGen Biotech
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented
March 04, 2025
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Announces Administration of First Dose of Troculeucel to Stroke Patient Under FDA-Cleared Compassionate Use Program
March 03, 2025
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Announces Administration of First Dose of Troculeucel to Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
February 21, 2025
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site
February 19, 2025
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimer’s Disease
February 13, 2025
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Receives U.S. FDA Fast Track Designation for Troculeucel for the Treatment of Moderate Alzheimer’s Disease
February 12, 2025
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Presents Phase 1/2a Troculeucel Data in Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 29, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Announces Upcoming Presentation at the 16th World Stroke Congress (WSC 2024)
October 15, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Announces Poster Presentations at the 17th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
October 08, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech’s Positive Phase 1 Clinical Data in Moderate Alzheimer’s Disease Advances Troculeucel into Phase 2 with First Patient Dosed in Phase 1/2a Trial
September 12, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 03, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
July 30, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International Conference
July 18, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech Appoints Dr. Marco Gottardis to its Board of Directors
July 15, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
JNJ
NKGN
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
June 12, 2024
From
NKGen Biotech
Via
GlobeNewswire
Tickers
NKGN
NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
May 02, 2023
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech, Inc. to Become Publicly Traded Company via Business Combination with Graf Acquisition Corp. IV
April 14, 2023
From
NKGen Biotech
Via
GlobeNewswire
Tickers
GFOR
NKGen Biotech Announces Formation of Scientific Advisory Board to Drive its Pipeline Strategy for Natural Killer Cell Therapies Targeting Neurodegenerative Diseases
March 08, 2023
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer
January 10, 2023
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Announces Collaboration with the Parkinson’s Foundation to Bring Its Novel Natural Killer Cell Therapy to the Clinic for Advanced Parkinson’s Disease
November 04, 2022
From
NKGen Biotech
Via
GlobeNewswire
NKGen Biotech Receives IND Clearance from FDA for SNK02 Allogeneic Natural Killer Cell Therapy for Solid Tumors
October 17, 2022
From
NKGen Biotech
Via
GlobeNewswire
